Protective neutralizing antibodies Antibodies produced by survivors of coronavirus disease 2019 (COVID-19) may be leveraged to develop therapies. A first step is identifying neutralizing antibodies, which confer strong protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Rogers et al. used a high-throughput pipeline to isolate and characterize monoclonal antibodies from convalescent donors. Antibodies were selected for binding to the viral spike protein, which facilitates entry into host cells by binding to the angiotensin-converting enzyme 2 (ACE2) receptor. Most isolated antibodies bound to regions of the spike outside of the receptor binding domain (RBD); however, a larger proportion of the RBD-binding antibodies were neutralizing, with the most potent binding at a site that overlaps the ACE2 binding site. Two of the neutralizing antibodies were tested in Syrian hamsters and provided protection against SARS-CoV-2 infection. Science , this issue p. 956 Passive transfer of a neutralizing antibody provides protection against disease in high-dose SARS-CoV-2 challenge in Syrian hamsters. Countermeasures to prevent and treat coronavirus disease 2019 (COVID-19) are a global health priority. We enrolled a cohort of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–recovered participants, developed neutralization assays to investigate antibody responses, adapted our high-throughput antibody generation pipeline to rapidly screen more than 1800 antibodies, and established an animal model to test protection. We isolated potent neutralizing antibodies (nAbs) to two epitopes on the receptor binding domain (RBD) and to distinct non-RBD epitopes on the spike (S) protein. As indicated by maintained weight and low lung viral titers in treated animals, the passive transfer of a nAb provides protection against disease in high-dose SARS-CoV-2 challenge in Syrian hamsters. The study suggests a role for nAbs in prophylaxis, and potentially therapy, of COVID-19. The nAbs also define protective epitopes to guide vaccine design.
【초록키워드】 COVID-19, coronavirus disease, neutralizing antibody, antibodies, SARS-CoV-2, ACE2, coronavirus, therapy, Neutralizing antibodies, antibody, hamsters, SARS-COV-2 infection, monoclonal antibody, Vaccine design, animal model, angiotensin-converting enzyme 2, Receptor binding domain, Prophylaxis, Protein, Cohort, Region, Health, Neutralization assay, RBD, Neutralizing, receptor, donors, hamster, convalescent, epitope, disease, Therapies, NAb, Protective, binding, host cell, passive transfer, Science, High-dose, viral spike protein, acute respiratory syndrome, Participants, overlap, ACE2 binding site, transfer, treat, MOST, survivor, countermeasure, responses, Prevent, enrolled, selected, produced, tested, develop, proportion, indicated, provided, facilitate, treated, provide, lung viral titer, RBD-binding antibody, 【제목키워드】 animal model, disease, SARS-CoV-2 neutralizing antibody,